472 related articles for article (PubMed ID: 29265948)
1. Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin.
Dierks J; Gaspersz MP; Belkouz A; van Vugt JLA; Coelen RJS; de Groot JWB; Ten Tije AJ; Meijer WG; Pruijt JFM; van Voorthuizen T; van Spronsen DJ; Rentinck M; Ten Oever D; Smit JM; Otten HM; van Gulik TM; Wilmink JW; Groot Koerkamp B; Klümpen H
Acta Oncol; 2018 Jun; 57(6):807-812. PubMed ID: 29265948
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
Kim MJ; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
BMC Cancer; 2008 Dec; 8():374. PubMed ID: 19091129
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study.
Siebenhüner AR; Seifert H; Bachmann H; Seifert B; Winder T; Feilchenfeldt J; Breitenstein S; Clavien PA; Stupp R; Knuth A; Pestalozzi B; Samaras P
BMC Cancer; 2018 Jan; 18(1):72. PubMed ID: 29325521
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients.
Kim BJ; Hyung J; Yoo C; Kim KP; Park SJ; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Cho H; Ryoo BY; Chang HM
Cancer Chemother Pharmacol; 2017 Jul; 80(1):209-215. PubMed ID: 28597043
[TBL] [Abstract][Full Text] [Related]
7. Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
Croitoru A; Gramaticu I; Dinu I; Gheorghe L; Alexandrescu S; Buica F; Luca I; Becheanu G; Herlea V; Simionov I; Hrehoret D; Lupescu I; Popescu I; Diculescu M
J Gastrointestin Liver Dis; 2012 Sep; 21(3):277-84. PubMed ID: 23012669
[TBL] [Abstract][Full Text] [Related]
8. Second-line chemotherapy in biliary tract cancer: Outcome and prognostic factors.
Schweitzer N; Kirstein MM; Kratzel AM; Mederacke YS; Fischer M; Manns MP; Vogel A
Liver Int; 2019 May; 39(5):914-923. PubMed ID: 30716200
[TBL] [Abstract][Full Text] [Related]
9. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
Morizane C; Okusaka T; Mizusawa J; Katayama H; Ueno M; Ikeda M; Ozaka M; Okano N; Sugimori K; Fukutomi A; Hara H; Mizuno N; Yanagimoto H; Wada K; Tobimatsu K; Yane K; Nakamori S; Yamaguchi H; Asagi A; Yukisawa S; Kojima Y; Kawabe K; Kawamoto Y; Sugimoto R; Iwai T; Nakamura K; Miyakawa H; Yamashita T; Hosokawa A; Ioka T; Kato N; Shioji K; Shimizu K; Nakagohri T; Kamata K; Ishii H; Furuse J;
Ann Oncol; 2019 Dec; 30(12):1950-1958. PubMed ID: 31566666
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma.
Thongprasert S; Napapan S; Charoentum C; Moonprakan S
Ann Oncol; 2005 Feb; 16(2):279-81. PubMed ID: 15668284
[TBL] [Abstract][Full Text] [Related]
11. Outcome and patterns of care in advanced biliary tract carcinoma (ABC): experience from two tertiary institutions in the United Kingdom.
Huggett MT; Passant H; Hurt C; Pereira SP; Bridgewater J; Mukherjee S
Tumori; 2014; 100(2):219-24. PubMed ID: 24852869
[TBL] [Abstract][Full Text] [Related]
12. Prognosis and prognostic factors in patients with advanced biliary tract cancer depending on its anatomical location.
Song BG; Park JK; Kim HS; Kim K; Park JK; Lee KH; Lee KT; Lee JK
Scand J Gastroenterol; 2019 Jun; 54(6):740-745. PubMed ID: 31136212
[No Abstract] [Full Text] [Related]
13. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
Moehler M; Maderer A; Schimanski C; Kanzler S; Denzer U; Kolligs FT; Ebert MP; Distelrath A; Geissler M; Trojan J; Schütz M; Berie L; Sauvigny C; Lammert F; Lohse A; Dollinger MM; Lindig U; Duerr EM; Lubomierski N; Zimmermann S; Wachtlin D; Kaiser AK; Schadmand-Fischer S; Galle PR; Woerns M;
Eur J Cancer; 2014 Dec; 50(18):3125-35. PubMed ID: 25446376
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy.
Suzuki Y; Kan M; Kimura G; Umemoto K; Watanabe K; Sasaki M; Takahashi H; Hashimoto Y; Imaoka H; Ohno I; Mitsunaga S; Ikeda M
J Gastroenterol; 2019 Mar; 54(3):281-290. PubMed ID: 30298469
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease.
Lamarca A; Benafif S; Ross P; Bridgewater J; Valle JW
Eur J Cancer; 2015 Sep; 51(13):1694-703. PubMed ID: 26066735
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study.
Feng K; Liu Y; Zhao Y; Yang Q; Dong L; Liu J; Li X; Zhao Z; Mei Q; Han W
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32487569
[TBL] [Abstract][Full Text] [Related]
18. PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.
Vogel A; Kasper S; Bitzer M; Block A; Sinn M; Schulze-Bergkamen H; Moehler M; Pfarr N; Endris V; Goeppert B; Merx K; Schnoy E; Siveke JT; Michl P; Waldschmidt D; Kuhlmann J; Geissler M; Kahl C; Evenkamp R; Schmidt T; Kuhlmann A; Weichert W; Kubicka S
Eur J Cancer; 2018 Mar; 92():11-19. PubMed ID: 29413685
[TBL] [Abstract][Full Text] [Related]
19. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.
Valle JW; Wasan H; Lopes A; Backen AC; Palmer DH; Morris K; Duggan M; Cunningham D; Anthoney DA; Corrie P; Madhusudan S; Maraveyas A; Ross PJ; Waters JS; Steward WP; Rees C; Beare S; Dive C; Bridgewater JA
Lancet Oncol; 2015 Aug; 16(8):967-78. PubMed ID: 26179201
[TBL] [Abstract][Full Text] [Related]
20. A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study.
Bridgewater J; Lopes A; Beare S; Duggan M; Lee D; Ricamara M; McEntee D; Sukumaran A; Wasan H; Valle JW
BMC Cancer; 2016 Feb; 16():153. PubMed ID: 26912134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]